Business Type Exporter, Supplier
API Form Liquid
Dosage As per Doctor's Prescription
Type Intravenous Administration
Click to view more

Preferred Buyer From

Location Worldwide

Product Details

Storage
Cool and Dry Place
Best Before
36 Months from Manufacturing

On January 28, 2016, the U. S. Food and Drug Administration approved eribulin (HALAVEN injection, Eisai Co., Ltd.) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.


 


HALAVEN is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting .

Yes! I am interested

Looking for "Eribulin Mesylate Injection" ?

Box

Explore More Products


Close

Raise your Query

Hi! Simply click below and type your query.

Our experts will reply you very soon.

WhatsApp Us